Wednesday, July 8, 2026

Patent intelligence · US

US 11116733

Topical dapsone and dapsone/adaplene compositions and methods for use thereof

granted A61KA61K31/136A61K31/145A61K31/192
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 308
Patent details — US 11116733
Jurisdiction
US
Status
granted
Grant date
Sep 14, 2021
Expiration
Sep 9, 2041
Applicant
ALMIRALL, LLC
Claims
14
CPC classes
A61K, A61K31/136, A61K31/145, A61K31/192
View on Google Patents ↗

Quick answer

US 11116733 (Topical dapsone and dapsone/adaplene compositions and methods for use thereof) is held by ALMIRALL, LLC. Status: granted. Granted Sep 14, 2021. Expires Sep 9, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ALMIRALL, LLC
Grant date
Expiration
Claims
14
CPC classes
A61K, A61K31/136, A61K31/145, A61K31/192, A61K47/10, A61K47/14

More from ALMIRALL, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 11116733?

US 11116733 (Topical dapsone and dapsone/adaplene compositions and methods for use thereof) is held by ALMIRALL, LLC. Status: granted. Granted Sep 14, 2021. Expires Sep 9, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11116733?

ALMIRALL, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 11116733 expire?

Our index shows an expiration date of Sep 9, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.